Clinical trial
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic…
NCT00067808 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00067808 |
|---|---|
| Title | Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) |
| Official title | Phase II Randomized Study of Three Different Schedules of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Eisai Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia |
| Intervention type | Drug |
| Interventions | Decitabine |
| Enrollment | 128 |
| Start date | Oct 1, 2003 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Aug 28, 2003 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: